United States in Vitro Diagnostics Industry Report

Detailed Analysis of The Medical Equipment & Medical Devices Market Covering Clinical Chemistry, Immunochemistry, Infectious Immunology, Microbiology, Genetic and Blood Test Reagents, Insturments and Test Kits

Product Code GMD04568
Publication Date May 2008
Publisher Global Markets Direct
Product Type Report
Pages 436
ISBN Number not applicable
Change currency
PDF £1,895.00 €2,282 $2,996 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

United States in Vitro Diagnostics Industry Report

Detailed Analysis of The Medical Equipment & Medical Devices Market Covering Clinical Chemistry, Immunochemistry, Infectious Immunology, Microbiology, Genetic and Blood Test Reagents, Insturments and Test Kits

This report is an essential source for in-depth information and data relating to the USA In Vitro Diagnostics devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the In Vitro Diagnostics in USA

Scope

  • The report provides sector information broken down into detailed categories and segments in country.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the industry at a global level, with break downs for the country
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
    • 2.2 Definitions
      • 2.2.1 In Vitro Diagnostics
  • 3 Healthcare Sector Review
    • 3.1 Healthcare Expenditure
    • 3.2 Healthcare Infrastructure
      • 3.2.1 Healthcare Personnel Data
      • 3.2.2 Healthcare Facilities Data
  • 4 In Vitro Diagnostics in United States
    • 4.1 In Vitro Diagnostics Overall Revenue (2000-2012)
    • 4.2 In Vitro Diagnostics Overall Company Share (2005-2006)
  • 5 Clinical Chemistry Test Reagents in United States
    • 5.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2012)
      • 5.1.1 Rapid Tests Overall Revenue (2000-2012)
      • 5.1.2 Laboratory Reagents Overall Revenue (2000-2012)
      • 5.1.3 Calibrators and Controls Overall Revenue (2000-2012)
    • 5.2 Clinical Chemistry Test Reagents Distribution Share (2005-2006)
    • 5.3 Clinical Chemistry Test Reagents Company Share (2005-2006)
  • 6 Immunochemistry Test Reagents in United States
    • 6.1 Immunochemistry Test Reagents Overall Revenue (2000-2012)
      • 6.1.1 Disease Specific Test Reagents Overall Revenue (2000-2012)
      • 6.1.2 Disease Specific Markers Overall Revenue (2000-2012)
      • 6.1.3 Hormone Related Testing Reagents Overall Revenue (2000-2012)
      • 6.1.4 Drug Related Testing Reagents Overall Revenue (2000-2012)
      • 6.1.5 Rapid Tests Overall Revenue (2000-2012)
      • 6.1.6 Calibrators and Controls Overall Revenue (2000-2012)
    • 6.2 Immunochemistry Test Reagents Distribution Share (2005-2006)
    • 6.3 Immunochemistry Test Reagents Company Share (2005-2006)
  • 7 Blood Test Reagents in United States
    • 7.1 Blood Test Reagents Overall Revenue (2000-2012)
      • 7.1.1 Haematology Test Reagents Overall Revenue (2000-2012)
      • 7.1.2 Hemostasis Test Reagents Overall Revenue (2000-2012)
      • 7.1.3 Monoclonal Antibodies Overall Revenue (2000-2012)
      • 7.1.4 Histology and Cytology Reagents Overall Revenue (2000-2012)
      • 7.1.5 Tissue Typing Reagents Overall Revenue (2000-2012)
      • 7.1.6 Cytokines and Immunomodulators Overall Revenue (2000-2012)
    • 7.2 Blood Test Reagents Distribution Share (2005-2006)
    • 7.3 Blood Test Reagents Company Share (2005-2006)
  • 8 Microbiology Test Reagents in United States
    • 8.1 Microbiology Test Reagents Overall Revenue (2000-2012)
      • 8.1.1 Bacteriology Test Reagents Overall Revenue (2000-2012)
      • 8.1.2 Rapid Tests Overall Revenue (2000-2012)
      • 8.1.3 Calibrators and Controls Overall Revenue (2000-2012)
    • 8.2 Microbiology Test Reagents Distribution Share (2005-2006)
    • 8.3 Microbiology Test Reagents Company Share (2005-2006)
  • 9 Infectious Immunology Test Reagents in United States
    • 9.1 Infectious Immunology Test Reagents Overall Revenue (2000-2012)
      • 9.1.1 Virology Overall Revenue (2000-2012)
      • 9.1.2 Bacteriology Overall Revenue (2000-2012)
      • 9.1.3 Parasitology Overall Revenue (2000-2012)
      • 9.1.4 Calibrators and Controls Overall Revenue (2000-2012)
      • 9.1.5 Rapid Tests Overall Revenue (2000-2012)
    • 9.2 Infectious Immunology Test Reagents Distribution Share (2005-2006)
    • 9.3 Infectious Immunology Test Reagents Company Share (2005-2006)
  • 10 Genetic Test Reagents in United States
    • 10.1 Genetic Test Reagents Overall Revenue (2000-2012)
    • 10.2 Genetic Test Reagents Distribution Share (2005-2006)
    • 10.3 Genetic Test Reagents Company Share (2005-2006)
  • 11 Self Testing in United States
    • 11.1 Self Testing Overall Revenue (2000-2012)
    • 11.2 Self Testing Distribution Share (2005-2006)
    • 11.3 Self Testing Company Share (2005-2006)
  • 12 Instruments in United States
    • 12.1 Instruments Overall Revenue (2000-2012)
    • 12.2 Instruments Distribution Share (2005-2006)
    • 12.3 Instruments Company Share (2005-2006)
  • 13 Abbott Laboratories Company Profile
    • 13.1 Company Overview
    • 13.2 Business Overview
      • 13.2.1 Products
      • 13.2.2 History
    • 13.3 Value Chain Analysis
      • 13.3.1 Manufacturing
      • 13.3.2 Product Development
      • 13.3.3 Clinical Trials
      • 13.3.4 Sales and Marketing
    • 13.4 SWOT Analysis
      • 13.4.1 Abbott Laboratories Strengths
      • 13.4.2 Abbott Laboratories Weaknesses
      • 13.4.3 Abbott Laboratories Opportunities
      • 13.4.4 Abbott Laboratories Threats
    • 13.5 Financial and Operational Review
      • 13.5.1 Financial Statements
      • 13.5.2 Financial Ratios
    • 13.6 Locations And Subsidiaries
      • 13.6.1 Head Office
      • 13.6.2 Other Locations & Subsidiaries
    • 13.7 Financial Deals Landscape
      • 13.7.1 Luminex Enters Into A Partnership Agreement With Abbott
      • 13.7.2 Evalve Secures $60 Million In Series D Financing
      • 13.7.3 Abbott Acquires Kos Pharmaceuticals
      • 13.7.4 Abbott Laboratories Enters Into An Agreement With Enanta Pharmaceuticals
      • 13.7.5 Abbott Laboratories Enters Into Distribution Agreement With Verax
      • 13.7.6 AstraZeneca Signs An Agreement With Abbott
      • 13.7.7 Abbott Laboratories Enters Into Licensing Agreement With Advanced Life Science
      • 13.7.8 Abbott Acquires Vascular Business Of Guidant From Boston Scientific
      • 13.7.9 Abbott Enters Into An Agreement With Axis-Shield
      • 13.7.10 Abbott Enters Into Licensing Agreement With Nephromics
      • 13.7.11 Abbott Enters Into Licensing Agreement With BioCurex
      • 13.7.12 Nihon Kohden And Abbott Laboratories Enter Into Commercialization Agreement
      • 13.7.13 Abbott Signs An Agreement With OraSure
      • 13.7.14 Abbott Enters Into Licensing Agreement With Cleveland Clinic
      • 13.7.15 Chattem Acquires Selsun Blue
      • 13.7.16 Abbott Terminates The Deal To Divest Its Divisions To GE Healthcare
      • 13.7.17 GE Healthcare terminates the acquisition of In vitro diagnostics and Point-of-Care diagnostics businesses of Abbott
    • 13.8 Recent Developments
      • 13.8.1 Apr 01, 2008: Abbott To Declare Q1 2008 Results
      • 13.8.2 Jan 23, 2008: Abbott Declares Q4 2007 Results
      • 13.8.3 Jan 03, 2008: Abbott To Declare Q4 And Year-End 2007 Results
    • 13.8
      • 13.8.5 Dec 14, 2007: Abbott Declares Quarterly Dividend
      • 13.8.6 Oct 17, 2007: Abbott Declares Q3 2007 Results
      • 13.8.7 Aug 03, 2007: Abbott COO To Retire
      • 13.8.8 Jul 18, 2007: Abbott Reports Q2 2007 Results
      • 13.8.9 Jul 11, 2007: Abbott Announces Termination Of Contract With GE
      • 13.8.10 Jun 14, 2007: Abbott Declares Quarterly Dividend
      • 13.8.11 Apr 18, 2007: Abbott Declares Quarterly Dividend
      • 13.8.12 Apr 18, 2007: Abbott Reports Q1 2007 Results
      • 13.8.13 Apr 10, 2007: Abbott Opens New Biotechnology Manufacturing Unit in Puerto Rico
      • 13.8.14 Jan 24, 2007: Abbott Declares Quarterly Dividend
      • 13.8.15 Jan 24, 2007: Abbott Reports Q4 2006 Results
      • 13.8.16 Jan 08, 2007: Abbott m2000 Instrument and Viral Load Tests for HIV-1 and HCV Approved in Canada
      • 13.8.17 Dec 20, 2006: Abbott To Voluntarily Delist From NYSE Arca
      • 13.8.18 Oct 18, 2006: Abbott Announces Share Repurchase Program
      • 13.8.19 Oct 18, 2006: Abbott Declares Quarterly Dividend
      • 13.8.20 Oct 18, 2006: Abbott Reports Q3 2006 Results
      • 13.8.21 Jul 19, 2006: Abbott Declares Quarterly Dividend
      • 13.8.22 Jul 19, 2006: Abbott Reports Q2 2006 Results
      • 13.8.23 Apr 19, 2006: Abbott Declares Quarterly Dividend
      • 13.8.24 Apr 19, 2006: Abbott Reports Q1 2006 Results
      • 13.8.25 Jan 20, 2006: Abbott Names New Director To The Board
    • 13.9 Abbott Laboratories Pipeline Products
      • 13.9.1 Fully Bioabsorbable Stent
      • 13.9.2 FreeStyle Navigator Continuous Glucose Monitoring System
      • 13.9.3 Wallis System
  • 14 Siemens Medical Solutions Company Profile
    • 14.1 Company Overview
    • 14.2 Business Overview
      • 14.2.1 Siemens Medical
      • 14.2.2 Products
      • 14.2.3 History
    • 14.3 Value Chain Analysis
      • 14.3.1 Manufacturing
      • 14.3.2 Product Development
      • 14.3.3 Sales and Marketing
    • 14.4 SWOT Analysis
      • 14.4.1 Siemens Medical Solutions Strengths
      • 14.4.2 Siemens Medical Solutions Weakness
      • 14.4.3 Siemens Medical Solutions Opportunities
      • 14.4.4 Siemens Medical Solutions Threats
    • 14.5 Locations And Subsidiaries
    • 14.6 Financial Deals Landscape
      • 14.6.1 Siemens Medical Acquires Dade Behring
      • 14.6.2 Siemens Medical Forms Joint Venture With Kameda Healthinformatics Institute
      • 14.6.3 Siemens Medical Acquires Gesellschaft fur Systemforschung und Dienstleistungen im Gesundheitswesen
      • 14.6.4 Siemens Medical Solutions Acquires Diagnostics Division Of Bayer Healthcare
      • 14.6.5 Siemens Medical Solutions Acquires German Healthcare IT Company GSD
      • 14.6.6 SonoSite And Siemens Enter Into Distribution Agreement
      • 14.6.7 Siemens Medical Solutions and IMPAC Medical Systems Of Elekta Group Enter Into Distribution Agreement
      • 14.6.8 Siemens Medical Acquires Sensant Corp
    • 14.7 Recent Developments
      • 14.7.1 Feb 28, 2008: Siemens Expects US Medical Market To Recover In 2009
      • 14.7.2 Jan 31, 2008: Siemens Repots Q1 FIscal 2008 Results
    • 14.8 Siemens Medical Solutions Pipeline Products
      • 14.8.1 DCA Vantage Analyzer
      • 14.8.2 Acuson S2000
      • 14.8.3 AXIOM Luminos dRF (Enhancements)
      • 14.8.4 Ysio wi-D
      • 14.8.5 Syngo DynaCT
      • 14.8.6 Syngo iGuide
      • 14.8.7 Syngo iPilot
      • 14.8.8 Siemens 7T MRI system
      • 14.8.9 Siemens 11.7T MRI system
      • 14.8.10 REMIND platform - REMIND Clinical Decision Support (CDS)
      • 14.8.11 Virtual Touch tissue imaging
      • 14.8.12 Virtual Touch tissue quantification
  • 15 F. Hoffmann-La Roche Ltd. Company Profile
    • 15.1 Company Overview
    • 15.2 Business Overview
      • 15.2.1 Diagnostics
      • 15.2.2 Pharmaceuticals
      • 15.2.3 Products
      • 15.2.4 History
    • 15.3 Value Chain Analysis
      • 15.3.1 Manufacturing
      • 15.3.2 Product Development
      • 15.3.3 Sales and Marketing
    • 15.4 SWOT Analysis
      • 15.4.1 F. Hoffmann-La Roche Ltd. Strengths
      • 15.4.2 F. Hoffmann-La Roche Ltd. Weaknesses
      • 15.4.3 F. Hoffmann-La Roche Ltd. Opportunities
      • 15.4.4 F. Hoffmann-La Roche Ltd. Threats
    • 15.5 Financial and Operational Review
    • 15.6 Locations And Subsidiaries
    • 15.7 Financial Deals Landscape
      • 15.7.1 Roche Acquires Ventana Medical Systems
      • 15.7.2 Roche Signs An Agreement With ACEA Biosciences
      • 15.7.3 Roche Signs Licensing Agreement With Ortho-Clinical Diagnostics And Novartis Vaccines & Diagnostics
      • 15.7.4 Roche Acquires Nimblegen
      • 15.7.5 Roche Signs An Agreement With Ipsen
      • 15.7.6 Roche Signs Licensing Agreement With Alnylam Pharmaceuticals
      • 15.7.7 Roche acquires BioVeris
      • 15.7.8 Roche Signs An Agreement With Toyama Chemical
      • 15.7.9 Roche Acquires 454 Life Sciences
      • 15.7.10 Roche And Transgene Enter Into A Partnership Agreement
      • 15.7.11 Roche Acquires Therapeutic Human Polyclonals
      • 15.7.12 Proacta, Inc. completes $35 million series B financing
      • 15.7.13 Roche Diagnostics Signs An Agreement With Multilyte
      • 15.7.14 Roche Diagnostics Signs An Agreement With ThromboGenics And Geymonat
      • 15.7.15 Roche Signs An Agreement With InterMune
      • 15.7.16 Roche Signs An Agreement With BioCryst Pharmaceuticals
      • 15.7.17 Roche Signs An Agreement With PDL BioPharma
      • 15.7.18 Innogenetics Signs An Agreement With Roche Diagnostics
      • 15.7.19 Roche Diagnostics Signs An Agreement With Response Biomedical
      • 15.7.20 Roche Acquires GLYCART biotechnology
      • 15.7.21 Roche Diagnostics Signs An Agreement With Amplimedical
      • 15.7.22 Roche Diagnostics Signs An Agreement With Exiqon
      • 15.7.23 Roche Signs An Agreement With 454 Life Sciences
      • 15.7.24 Roche Diagnostics Signs An Agreement With bioMerieux
      • 15.7.25 Roche Sells Roche Consumer Health To Bayer HealthCare
      • 15.7.26 Roche Signs An Agreement With deCODE genetics
      • 15.7.27 Roche Signs An Agreement With PDL BioPharma
      • 15.7.28 Roche Signs An Agreement With Japan Tobacco
      • 15.7.29 Roche Diagnostics Signs An Agreement With Institut Pasteur And Bio-Rad Laboratories
      • 15.7.30 Roche Diagnostics Signs An Agreement With Ortho-Clinical Diagnostics
      • 15.7.31 Roche Diagnostics Signs An Agreement With Inverness Medical
      • 15.7.32 Roche To Sell Three Pharmaceutical Products To Actavis
    • 15.8 Recent Developments
      • 15.8.1 Jan 30, 2008: Roche Reports 2007 Results
      • 15.8.2 Oct 23, 2007: Roche Considers Legal Options In Patent Litigation Case
      • 15.8.3 Oct 16, 2007: Roche Declares First Nine Months 2007 Results
      • 15.8.4 Oct 02, 2007: Roche Names New CEO For Diagnostics Division
      • 15.8.5 Jul 19, 2007: Roche Reports H1 2007 Results
      • 15.8.6 May 30, 2007: NorDiag Enters Distribution Agreement With Roche
      • 15.8.7 Feb 07, 2007: Roche Reports Full-Year 2006 Results
      • 15.8.8 Oct 17, 2006: Roche Reports Nine-Months Ended 2006 Results
  • 16 Beckman Coulter, Inc. Company Profile
    • 16.1 Company Overview
    • 16.2 Business Overview
      • 16.2.1 Cellular Systems
      • 16.2.2 Chemistry Systems
      • 16.2.3 Discovery and Automation Systems
      • 16.2.4 Immunoassay Systems
      • 16.2.5 Products
      • 16.2.6 History
    • 16.3 Value Chain Analysis
      • 16.3.1 Manufacturing
      • 16.3.2 Product Development
      • 16.3.3 Sales and Marketing
    • 16.4 SWOT Analysis
      • 16.4.1 Beckman Coulter, Inc. Strengths
      • 16.4.2 Beckman Coulter, Inc. Weaknesses
      • 16.4.3 Beckman Coulter, Inc. Opportunities
      • 16.4.4 Beckman Coulter, Inc. Threats
    • 16.5 Financial and Operational Review
    • 16.6 Locations And Subsidiaries
    • 16.7 Financial Deals Landscape
      • 16.7.1 AcroMetrix Enters Into A Partnership Agreement With Beckman Coulter
      • 16.7.2 Beckman Coulter Enters Into Licensing Agreements For Molecular Tests With National University of Ireland
      • 16.7.3 Beckman Coulter Acquires Flow Cytometry Instrumentation Business From Dako
      • 16.7.4 Beckman Coulter Acquires NexGen Diagnostics
      • 16.7.5 Beckman Coulter Signs An Agreement With Johns Hopkins University
      • 16.7.6 Beckman Coulter Grants Sublicense To Dade Behring
      • 16.7.7 Beckman Coulter Completes Private Placement Of $600 Million
      • 16.7.8 Beckman Coulter Acquires Lumigen
      • 16.7.9 Beckman Coulter Signs Licensing Agreement With Roche
      • 16.7.10 Beckman Coulter Acquires Agencourt Bioscience
      • 16.7.11 Beckman Coulter to aqcuire Biosite
    • 16.8 Recent Developments
      • 16.8.1 Feb 08, 2008: Beckman Names New Chairman
      • 16.8.2 Feb 08, 2008: Beckman Declares Quarterly Dividend
      • 16.8.3 Dec 12, 2007: Beckman Elects New Board Member
      • 16.8.4 Nov 07, 2007: Beckman Signs Agreements With MedAssets
      • 16.8.5 Oct 22, 2007: Beckman Declares Quarterly Dividend
      • 16.8.6 Jul 26, 2007: Beckman Declares Quarterly Dividend
      • 16.8.7 Jun 04, 2007: Beckman Board Member Resigns
      • 16.8.8 May 03, 2007: Beckman Declares Quarterly Dividend
      • 16.8.9 May 02, 2007: Beckman Q1 Revenue Up 7.8% To $613.6 Million
      • 16.8.10 Apr 02, 2007: Beckman Signs Pact With Premier To Provide Core Laboratory Systems
      • 16.8.11 Jan 10, 2007: Beckman Coulter Streamlines Operations
      • 16.8.12 Oct 10, 2006: Beckman Coulter Appoints New Vice President and CFO
      • 16.8.13 Aug 01, 2006: Beckman Announces Arbitration Results With Digene
      • 16.8.14 Apr 27, 2006: Beckman Coulter Provides Information On Applera Settlement
    • 16.9 Beckman Coulter, Inc. Pipeline Products
      • 16.9.1 Sex Hormone Binding Globulin Test
      • 16.9.2 sVEGF-R1
      • 16.9.3 EPO assay
      • 16.9.4 ProClot (Protein C) for ACL TOP
      • 16.9.5 ProS (Protein S) for ACL TOP
      • 16.9.6 Factor VIII for ACL TOP
      • 16.9.7 Tricyclics
      • 16.9.8 Ischemia Modified Albumin
      • 16.9.9 ANA Screen
      • 16.9.10 Product Overview
      • 16.9.11 Product Description
      • 16.9.12 Product Status
      • 16.9.13 Soluble Transferrin Receptor
      • 16.9.14 PT-Fib for ACL TOP
      • 16.9.15 PT-Fib HS for ACL TOP
      • 16.9.16 PT-Fib HS Plus for ACL TOP
      • 16.9.17 Rubella IgM
      • 16.9.18 Anti-Cardiolipin
      • 16.9.19 ds DNA Ab
      • 16.9.20 Inhibin A
      • 16.9.21 Anti-dsDNA
      • 16.9.22 Immunoassay for sepsis
      • 16.9.23 Tests for hospital acquired infections
      • 16.9.24 Chlamydia test
      • 16.9.25 Neisseria test
  • 17 Dade Behring Holdings, Inc. Company Profile
    • 17.1 Company Overview
      • 17.1.1 Products
    • 17.2 Locations And Subsidiaries
    • 17.3 Financial Deals Landscape
      • 17.3.1 Siemens Medical Acquires Dade Behring
      • 17.3.2 Beckman Coulter Grants Sublicense To Dade Behring
    • 17.4 Recent Developments
      • 17.4.1 Jul 23, 2007: Dade Behring Declares Quarterly Cash Dividend
      • 17.4.2 May 08, 2007: Dade Behring Declares Quarterly Cash Dividend
      • 17.4.3 Feb 13, 2007: Dade Behring Declares Quarterly Cash Dividend
    • 17.5 Dade Behring Holdings, Inc. Pipeline Products
      • 17.5.1 Innovance D-DIMER
  • 18 Regulation System
    • 18.1 Medical Equipment Approval Process
      • 18.1.1 Pre-market Approval Process
      • 18.1.2 Intended use and Indications for use
      • 18.1.3 Predicate Device
      • 18.1.4 Safe and Effective
      • 18.1.5 Other Category Devices
      • 18.1.6 Post-Market Approval Process
      • 18.1.7 Compliance and Enforcement
      • 18.1.8 Registration Fee
      • 18.1.9 Approval Time
  • 19 Pricing and Reimbursement
    • 19.1 Government Policies
    • 19.2 Private Insurance
    • 19.3 Diagnosis Related Groups (DRG)
  • 20 Distribution Structure
    • 20.1 Distribution Structure
  • 21 APPENDIX
    • 21.1 Global Markets Direct Research Methodology
    • 21.2 Coverage
    • 21.3 Secondary Research
    • 21.4 Primary Research
    • 21.5 Models
    • 21.6 Forecasts
    • 21.7 Expert Panels
    • 21.8 Currency Conversion
    • 21.9 Contact Us
    • 21.10 Disclaimer
  • List of Tables
    • Table 1: United States Healthcare Expenditure, 2003-2010
    • Table 2: United States Healthcare Expenditure by Age (per person), 2000-2003
    • Table 3: United States Healthcare Expenditure by Sex (per person), 2000-2003
    • Table 4: United States Healthcare Expenditure by Race (per person), 2000-2003
    • Table 5: United States Personal Healthcare Expenditure by Type, 2000-2004
    • Table 6: United States Personal Healthcare Expenditure by Source, 2000-2004
    • Table 7: Total Number of Doctors in the United States, 2003-2010
    • Table 8: Number of Doctors by Specialty in the United States, 2003-2010
    • Table 9: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004
    • Table 10: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004 (Cont.)
    • Table 11: Total Hospitals in the United States, 2000-2004
    • Table 12: Community Hospitals by Number of Beds in the United States, 2000-2004
    • Table 13: Number of Hospital Beds in the United States, 2000-2004
    • Table 14: Number of Hospital Beds by Range in the United States, 2000-2004
    • Table 15: In Vitro Diagnostics, United States, Overall Revenues ($ mn), 2000-2012
    • Table 16: In Vitro Diagnostics, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 17: In Vitro Diagnostics, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 18: In Vitro Diagnostics, United States, Category Revenues ($ mn), 2000-2012
    • Table 19: In Vitro Diagnostics, United States, Category Revenues ($ mn), Historic, 2000-2007
    • Table 20: In Vitro Diagnostics, United States, Category Revenues ($ mn), Forecast, 2007-2012
    • Table 21: In Vitro Diagnostics, United States, Overall Company Share by Revenue, 2005-2006
    • Table 22: Clinical Chemistry Test Reagents, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 23: Clinical Chemistry Test Reagents, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 24: Clinical Chemistry Test Reagents, United States, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 25: Clinical Chemistry Test Reagents, United States, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 26: Rapid Tests, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 27: Rapid Tests, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 28: Laboratory Reagents, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 29: Laboratory Reagents, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 30: Calibrators and Controls, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 31: Calibrators and Controls, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 32: Clinical Chemistry Test Reagents, United States, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 33: Clinical Chemistry Test Reagents, United States, Company Share by Revenue ($ mn), 2005-2006
    • Table 34: Immunochemistry Test Reagents, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 35: Immunochemistry Test Reagents, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 36: Immunochemistry Test Reagents, United States, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 37: Immunochemistry Test Reagents, United States, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 38: Disease Specific Test Reagents, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 39: Disease Specific Test Reagents, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 40: Disease Specific Test Reagents, United States, Revenue by Sub-Segment ($ mn), Historic, 2000-2007
    • Table 41: Disease Specific Test Reagents, United States, Revenue by Sub-Segment ($ mn), Forecast, 2007-2012
    • Table 42: Allergy, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 43: Allergy, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 44: Anaemia/ Vitamins, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 45: Anaemia/ Vitamins, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 46: Rheumatoid Disease, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 47: Rheumatoid Disease, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 48: Auto-Immune Disease, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 49: Auto-Immune Disease, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 50: Disease Specific Markers, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 51: Disease Specific Markers, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 52: Disease Specific Markers, United States, Revenue by Sub-Segment ($ mn), Historic, 2000-2007
      • ble 53: Disease Specific Markers, United States, Revenue by Sub-Segment ($ mn), Forecast, 2007-2012
    • Table 54: Tumour Markers, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 55: Tumour Markers, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 56: Cardiac Markers, United States, Revenue by Sub-Segment ($ mn), Historic, 2000-2007
    • Table 57: Cardiac Markers, United States, Revenue by Sub-Segment ($ mn), Forecast, 2007-2012
    • Table 58: Hormone Related Testing Reagents, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 59: Hormone Related Testing Reagents, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 60: Hormone Related Testing Reagents, United States, Revenue by Sub-Segment ($ mn), Historic, 2000-2007
    • Table 61: Hormone Related Testing Reagents, United States, Revenue by Sub-Segment ($ mn), Forecast, 2007-2012
    • Table 62: Specific Proteins, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 63: Specific Proteins, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 64: Fertility and Pregnancy, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 65: Fertility and Pregnancy, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 66: Individual/ Specified Hormones, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 67: Individual/ Specified hormones, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 68: Specific Organ Function, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 69: Specific Organ Function, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 70: Drug Related Testing Reagents, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 71: Drug Related Testing Reagents, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 72: Drug Related Testing Reagents, United States, Revenue by Sub-Segment ($ mn), Historic, 2000-2007
    • Table 73: Drug Related Testing Reagents, United States, Revenue by Sub-Segment ($ mn), Forecast, 2007-2012
    • Table 74: Therapeutic Drugs, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 75: Therapeutic Drugs, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 76: Drug of Abuse and Toxicology, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 77: Drug of Abuse and Toxicology, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 78: Rapid Tests, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 79: Rapid Tests, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 80: Calibrators and Controls, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 81: Calibrators and Controls, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 82: Immunochemistry Test Reagents, United States, Distribution Share by Revenue ($ mn), 2005-2006